Skip to main content
. 2021 May 25;120:S95–S105. doi: 10.1016/j.jfma.2021.05.020

Table 3.

Base case results of the cost-effectiveness analysis for three COVID-19 vaccines.

Strategy Effectiveness (QALD) Incremental QALD Cost (USD) Incremental cost ICUR
Vaccination
Moderna 179.8286 0.8284 155.4759 −266.0500 −321.1441
Pfizer 179.8120 0.8119 131.8955 −289.6303 −356.7512
AstraZeneca 179.7458 0.7456 166.9397 −254.5862 −341.4381
No vaccination 179.0002 421.5258

ICUR: incremental cost-utility ratio; QALD: quality-adjusted life day.